|
|
|
LifeScienceHistory.com - Check us out on Instagram
Take Your Next Career Step with Lundback
California Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2023 replacing CaliforniaLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
Aeolus Pharmaceuticals, Inc.
| | | Phone: | (949) 481-9825 | Year Established: | 1994 | Employees: | 4 | Ticker: | AOLS | Exchange: | OTCQB | Main Contact: | David C. Cavalier, Chairman & CFO | | Other Contacts: | Christopher Stanley, VP, Operations Brian J. Day, Ph.D., CSO John L. McManus, CEO
| | Company Description | Aeolus Pharmaceuticals (formerly Intercardia and Incara Pharmaceuticals) is developing a new class of broad-spectrum, catalytic-antioxidant compounds that protect healthy tissue from the damaging effects of radiation. Its first compound, AEOL 10150, is being developed, with funding by the US Department of Health and Human Services, as a medical countermeasure against chemical and radiological weapons, where its initial target indications are as a protective agent against the effects of acute radiation syndrome and delayed effects of acute radiation exposure. Aeolus' strategy is to leverage the substantial investment in toxicology, manufacturing, and preclinical and clinical studies made by US Government agencies in AEOL 10150, including the contract with BARDA valued, with options, at up to $118.4 million, to efficiently develop the compound for use in idiopathic pulmonary fibrosis and oncology. | |
|
|
|
|
|